Life Science Leader — April 2013 Outsourcing and the oral solid dose: Will challenges lead to new patterns of outsourcing? Life Science Leader — CRO Leadership Awards supplement issue Strategic Outsourcing Often Means Combining Functional and Full-Service CROs 
 
May 10 Life Science Leader's May issue includes results from Nice Insight annual research April 10 Learn about Trends in Outsourcing the Oral Solid Dose in April's Outsourcing Insights 
"Nice Insight’s thought-provoking data gave me new insight into existing
companies that outsource research and manufacturing services and products."
Director of Chemical Product R&D, Specialty Pharmaceutical Company, North America  
CPhI Worldwide
October 22-24 Messe Frankfurt, Germany |
Accugenix, Inc. Adpen Laboratories Inc. Advanced Biotechnologies Inc. Bio-Technical Resources BioBlocks, Inc. GenScript USA Inc. Optivia Biotechnology, Inc. Bio-Synthesis, Inc.
Bio-Synthesis, Inc., a chemical biology contract research organization, specializes in constructing bio-conjugates including but not limited to peptides, DNA, RNA, small drugs and other compounds. The first producer of commercially available synthetic DNA, the company has added DNA paternity testing, DNA HLA typing, PNAs, genomic sequencing, fluorescence-based genotyping, custom organic synthesis and other molecular-biology-based applications. It is currently active in the areas of proteomics, epigenetics, synthetic biology, carbohydrate chemistry, synthetic peptides and others. http://www.biosyn.com
Regions
Americas Stock Symbol Private Filter of Bio-Synthesis, Inc.'s services per Nice Insight Categories
Contact Bio-Synthesis, Inc. 
|
|
|
